Study of Microbiological Safety of 25 Oncology Drugs After Multiple Uses in Aseptic Conditions
Author(s): Roy Julie, Brault Julie, Joran Pierre, Metrop Raphael, Hildgen Patrice
Issue: Sep/Oct 2011 - Volume 15, Number 5
View All Articles in Issue
Page(s): 428-434
Download in electronic PDF format for $75
Abstract: The purpose of this study was to determine the microbiological safety of 25 widely used antineoplastic drugs in order to establish if it is possible to safely use them, after opening, past the 24-hour period that most manufacturers suggest. This is one of the first microbiological studies undertaken for these 25 drugs. The studied antineoplastics were kept following their respective physicochemical stability conservation conditions, which are already well documented and known. All manipulations were performed in the cleanroom of a hospital oncology pharmacy, following aseptic procedures. To reveal potential contaminations (bacterial or mycological) after being opened, the drugs were tested many times and inoculated on many different types of media: TSB Broth (or TSA Agar for colored drugs), Blood Agar Base, and Sabouraud Agar. The tests were performed on the day of opening (Day 0), then again once or twice up to 14 days (on Days 4, 7, or 14) based upon known physicochemical stability. Positive and negative controls were also performed for each type of culture in order to validate the method. No bacterial growth was encountered except for two Blood Agar Bases, where one colony grew. More growth was encountered for the mycological medias (13.9%), but it was considered random since Sabouraud Agar negative controls were 10% contaminated. Twenty-two of the studied drugs were considered microbiologically stable for their studied conditions of conservation (4, 7, or 14 days). The remaining three studied drugs did not conclusively show their microbiological stability. The results suggest that 22 antineoplastic drugs could be kept longer after opening without compromising patient safety. In literature, data exists on the physicochemical stability for these drugs. Generally, pharmaceutical companies recommend that the majority of these drugs shouldn’t be used after an 8-hour period. Therefore, the results of this study can allow for a significant savings in terms of hospital budget by extending the length of usage. However, caution should be exercised when examining these results because the architecture of the cleanrooms cannot be reproduced and because it can have significant impact on the results and safety. Therefore, an internal validation process should be undertaken for each of the pharmacy settings prior to generalizing these results.
Related Keywords:
antineoplastic agents, anticancer agents, cancer chemotherapy, microbial contamination, stability, bacterial contamination, fungal contamination
Related Categories:
CANCER AND AIDS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, QUALITY CONTROL, INFECTIOUS DISEASE, STORAGE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Study of Microbiological Safety of 25 Oncology Drugs After Multiple Uses in Aseptic Conditions
Roy Julie, Brault Julie, Joran Pierre, Metrop Raphael, Hildgen Patrice
|
Sep/Oct 2011
Pg. 428-434
|
Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
|
Jul/Aug 2001
Pg. 310-312
|
Physicochemical and Microbiological Stability of Azathioprine in InOrpha Suspending Agent Studied Under Various Conditions
Amin Alexandre, Bourget Philippe, Vidal Fabrice, Cartier Francois, Beauvais Raphaelle, Do Nascimento Afonso Veronica
|
Jan/Feb 2015
Pg. 73-77
|
Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition
Bourget Philippe, Amin Alexandre, Vidal Fabrice, Pieyre Manon, Dosso El Ourmar, Beauvais Raphaelle, Loeuillet Richard
|
Sep/Oct 2014
Pg. 427-431
|
Antineoplastic Drug Contamination on the Outside of Prepared Infusion Bags
Breukels Oscar, van der Gronde Toon, Simons-Sanders Kathleen, Crul Mirjam
|
Jul/Aug 2018
Pg. 345-349
|
Five Compounds for Treating Diabetes-Related Conditions
Meece Jerry
|
May/Jun 2003
Pg. 170-174
|
Basics of Compounding for Hazardous Drugs, Part 2: Regulation and Sources of Contamination
Allen Loyd V Jr
|
Nov/Dec 2006
Pg. 446-448
|
Sterile Basics of Compounding: Contamination Control Strategies, Part 2
Summers Amy
|
Nov/Dec 2022
Pg. 497-504
|
Basics of Sterile Compounding: Contamination Control
Akers Michael J
|
May/Jun 2015
Pg. 232-238
|
Basics of Compounding for the Treatment of Warts
Allen Loyd V Jr
|
Mar/Apr 2004
Pg. 126-129
|
Extending Practical (In Use) Shelf Life of Oncology Drug Vials Using Spikes
de Wilde Sofieke, Crul Mirjam, Breukels Oscar
|
Mar/Apr 2023
Pg. 154-159
|
Establishing Benchmark Rates of Microbial and Bacterial Endotoxin Contamination for Radiopharmaceuticals Compounded in Commerical Nuclear Pharmacy Settings
Weatherman Kara D, Augustine Samuel, Christoff Jeffrey, Galbraith Wendy
|
Mar/Apr 2013
Pg. 168-174
|
Contamination Control in Compounding Areas
Mulder Kyle, Gonzales Ben A
|
Jul/Aug 2019
Pg. 271-278
|
Sterile Basics of Compounding: Contamination Control Strategies, Part 1
Summers Amy
|
Sep/Oct 2022
Pg. 411-418
|
Roboticized Compounding of Oncology Drugs in a Hospital Pharmacy
Palma Elisabetta, Bufarini Celestino
|
Sep/Oct 2014
Pg. 358-364
|
Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding
Soefje Scott, Rickabaugh Keith, Rajkumar Rahul, Wall Kathryn P
|
Nov/Dec 2021
Pg. 515-522
|
Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding (Reprint)
Soefje Scott, Rickabaugh Keith, Rajkumar Rahul, Wall Kathryn P
|
Jan/Feb 2022
Pg. 72-79
|
Compounding for the Effects of Weapons of Mass Destruction
Sammarco Domenic A
|
Jan/Feb 2003
Pg. 10-15
View Sample |
Basics of Sterile Compounding: Excipients Used in Injections
Akers Michael J
|
Jul/Aug 2017
Pg. 301-308
|
Antineoplastic Agents
Ashworth Lisa D
|
Jul/Aug 2001
Pg. 268-271
|
Return to Top |